NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
12.74
+0.50 (4.08%)
May 1, 2024, 4:00 PM EDT - Market closed
NovoCure Revenue
In the year 2023, NovoCure had annual revenue of $509.34M, a decrease of -5.30%. Revenue in the quarter ending December 31, 2023 was $133.78M with 4.17% year-over-year growth.
Revenue (ttm)
$509.34M
Revenue Growth
-5.30%
P/S Ratio
2.68
Revenue / Employee
$350,542
Employees
1,453
Market Cap
1.37B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
Dec 31, 2021 | 535.03M | 40.67M | 8.23% |
Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
Dec 31, 2019 | 351.32M | 103.25M | 41.62% |
Dec 31, 2018 | 248.07M | 71.04M | 40.13% |
Dec 31, 2017 | 177.03M | 94.14M | 113.57% |
Dec 31, 2016 | 82.89M | 49.80M | 150.52% |
Dec 31, 2015 | 33.09M | 17.60M | 113.60% |
Dec 31, 2014 | 15.49M | 5.13M | 49.53% |
Dec 31, 2013 | 10.36M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AdaptHealth | 3.20B |
Brookdale Senior Living | 3.02B |
Agiliti | 1.17B |
Ironwood Pharmaceuticals | 442.74M |
Kiniksa Pharmaceuticals | 301.77M |
Establishment Labs Holdings | 165.15M |
NVCR News
- 7 days ago - Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 - Business Wire
- 26 days ago - Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 - Business Wire
- 4 weeks ago - Novocure to Report First Quarter 2024 Financial Results - Business Wire
- 5 weeks ago - Novocure's stock surges after positive results in brain-cancer trial - Market Watch
- 5 weeks ago - Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer - Business Wire
- 5 weeks ago - Novocure's lung cancer therapy succeeds in late-stage trial - Reuters
- 5 weeks ago - METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer - Business Wire
- 7 weeks ago - INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO - Business Wire